Galapagos Initiates a Phase 2a Study with GLPG1690

News   Apr 07, 2016

 
Galapagos Initiates a Phase 2a Study with GLPG1690
 
 
 

RELATED ARTICLES

Stable Beta-Amyloid Dimers Identified in Alzheimer’s Brains

News

A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.

READ MORE

Reversing an Unstoppable Cancer Cascade with Proteomics

News

Mutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.

READ MORE

The Protein and the Paupar

News

Non-coding RNAs (ncRNA) exist in a limbo within cells, having been created from genes but never destined to be turned into functional protein. A ncRNA called Paupar has been shown to regulate a protein controlling brain growth, a first for these mysterious molecules.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE